-
1دورية أكاديمية
المؤلفون: Crona, Daniel J., Skol, Andrew D., Leppänen, Veli-Matti, Glubb, Dylan M., Etheridge, Amy S., Hilliard, Eleanor, Pena, Carol E., Peterson, Yuri K., Klauber-DeMore, Nancy, Alitalo, Kari K., Innocenti, Federico
المساهمون: Kari Alitalo / Principal Investigator, University of Helsinki, HUSLAB, CAN-PRO - Translational Cancer Medicine Program
مصطلحات موضوعية: FACTOR-TARGETED THERAPY, MULTIKINASE INHIBITOR, LIGAND-BINDING, GROWTH, CANCER, ANGIOGENESIS, ASSOCIATION, ACTIVATION, MECHANISMS, 3111 Biomedicine, 3122 Cancers
وصف الملف: application/pdf
العلاقة: This work was supported by grants NIH/NCI R21CA178550-01 (to N. Klauber-DeMore and F. Innocenti), NIH/NCI R21CA139280-01 (to F. Innocenti), NIH/NCI K07CA140390-01 (to F. Innocenti), Cancer Research Foundation Young Investigator Award (to F. Innocenti), NIGMS T32GM086330 (to D.J. Crona), American Foundation for Pharmaceutical Education Fellowship (to D.J. Crona), the Jane and Aatos Erkko Foundation (to K.K. Alitalo), European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement no. 743155 (to K.K. Alitalo), Jenny and Antti Wihuri Foundation (to K.K. Alitalo), the Academy of Finland Centre of Excellence Program 2014-2019 (271845 and 307366 to K.K. Alitalo), and the Sigrid Juselius Foundation (to K.K. Alitalo). We would like to acknowledge Dr. Habibul Ahsan and Dr. Muhammad Kibriya of the University of Chicago genotyping core, as well as Mr. Jason Luo of the University of North Carolina-Chapel Hill Mammalian Genotyping Core. We would like to thank Dr. Kurt Ballmer-Hofer for his advice and assistance. Finally, we would like to acknowledge Ms. Jessie Bishop, Mrs. Anna Crollman, Dr. Lana Crona, Ms. Kelli Hammond, and Ms. Sara Pettaway, and Dr. William Scott for their assistance in editing and formatting this paper.; Crona , D J , Skol , A D , Leppänen , V-M , Glubb , D M , Etheridge , A S , Hilliard , E , Pena , C E , Peterson , Y K , Klauber-DeMore , N , Alitalo , K K & Innocenti , F 2019 , ' Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib ' , Cancer Research , vol. 79 , no. 1 , pp. 231-241 . https://doi.org/10.1158/0008-5472.CAN-18-1089Test; 85059485846; 11909248-9b16-4aa8-9a3f-d83bd1e75acb; http://hdl.handle.net/10138/313220Test; 000454833400021
-
2دورية أكاديمية
المؤلفون: Sasaki, Mark M., Skol, Andrew D., Bao, Riyue, Rhodes, Lindsay V., Chambers, Rachelle, Vokes, Everett E., Cohen, Ezra E. W., Onel, Kenan
المصدر: Cancer Epidemiology, Biomarkers & Prevention; Aug2015, Vol. 24 Issue 8, p1222-1228, 7p